Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose IL-2 (ILT-101) in Established Type 1 Diabetes
NCT03243058Phase 2Withdrawn
- Start
- Jun 2023
- Primary completion
- Dec 2026
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aldesleukin in type 1 diabetes mellitus (T1D) (3 arms). Primary endpoint: C-peptide response at 1 year. Planned start Jun 2023; status: withdrawn.
02
Drugs
aldesleukin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03243058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03243058.